Sculptra Dermik Laboratories - Treatment for Facial Lipoatrophy in HIV Patients
Sculptra is used for the restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with human immunodeficiency virus.Posted: August 2004
Related Articles:
- FDA Approves Sculptra Aesthetic, a Facial Injectable for Correction of Nasolabial Folds and Other Facial Wrinkles - July 29, 2009
- Sculptra From Dermik Laboratories Receives Recommendation For Approval With Conditions From FDA Advisory Panel - March 26, 2004
- Aventis' Dermik Laboratories Announces FDA Acceptance of Filing For Sculptra to Treat Facial Lipoatrophy - February 6, 2004
Sculptra (injectable poly-L-lactic acid) FDA Approval History
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.